Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Bone Health or Osteoporosis?
The honest map across 8 bone health scenarios — what is FDA-approved, where bisphosphonates rule, and how the three FDA-approved peptide anabolic therapies fit.
WHICH BONE HEALTH CONTEXT?
Bone Health Context
Animal Studies
Human Trials
Postmenopausal osteoporosis at moderate fracture risk
validated bisphosphonate first-line
Postmenopausal osteoporosis at high fracture risk
FDA-approved anabolic peptide therapy
Male osteoporosis
FDA-approved anabolic and antiresorptive options
Glucocorticoid-induced osteoporosis
FDA-approved Teriparatide preferred per ACR 2017
Severe osteoporosis with prior fragility fracture
anabolic-first sequential therapy
Osteoporosis prevention with osteopenia
lifestyle and SERMs
Bisphosphonate intolerance or contraindication
FDA-approved alternatives
Tendon and bone fracture healing research
research-grade context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Bone health and osteoporosis have well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by primary care, endocrinology, rheumatology, or geriatrics. Workup covers DEXA bone density T-score, FRAX 10-year fracture risk, calcium, vitamin D, and biochemical markers. Additional assessment includes secondary cause evaluation when clinically indicated.
Validated bone health therapy is foundational. Bisphosphonates are first-line per AACE/ACE 2020 for moderate fracture risk. Denosumab (Prolia) is FDA-approved RANKL inhibitor alternative.
Teriparatide is FDA-approved as Forteo for postmenopausal osteoporosis, men with osteoporosis, and glucocorticoid-induced osteoporosis. Phase 3 evidence demonstrated approximately 65 percent reduction in vertebral fractures.
Abaloparatide is FDA-approved as Tymlos for postmenopausal and male osteoporosis at high fracture risk. ACTIVE Phase 3 demonstrated fracture reduction.
Romosozumab is FDA-approved as Evenity for postmenopausal osteoporosis at high fracture risk. ARCH and FRAME Phase 3 trials demonstrated fracture reduction.
Calcitonin is FDA-approved as Miacalcin for postmenopausal osteoporosis. Salmon calcitonin nasal spray use has declined due to malignancy concerns.
BPC-157 is research-grade with limited clinical evidence in bone contexts.
The honest framing: three peptides hold direct FDA-approved osteoporosis indications. Validated bisphosphonates, denosumab, calcium, and vitamin D remain foundational. For broader context, see Peptides for Tendon Repair, Peptides for Recovery After Surgery, and Peptides for Menopause.
Anabolic peptides vs antiresorptive bisphosphonates for osteoporosis
FDA-approved Teriparatide and Abaloparatide vs alendronate, risedronate, zoledronic acid
Bisphosphonates are validated first-line antiresorptive therapy per AACE/ACE 2020 for moderate fracture risk. Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast) are FDA-approved options with substantial Phase 3 fracture reduction evidence. Mechanism is osteoclast inhibition through farnesyl pyrophosphate synthase blockade. Vertebral fracture reduction is approximately 40-70 percent. Treatment duration is typically 3-5 years with drug holiday consideration.
FDA-approved anabolic peptides hold positioning for high fracture risk per AACE/ACE 2020. Teriparatide (Forteo, recombinant PTH 1-34) demonstrated approximately 65 percent vertebral fracture reduction in Phase 3. Abaloparatide (Tymlos, PTHrP analog) demonstrated approximately 86 percent vertebral fracture reduction in ACTIVE Phase 3. Mechanism is osteoblast stimulation producing net anabolic bone formation. Treatment is limited to 2 years lifetime due to osteosarcoma concerns from preclinical rat studies. Sequential antiresorptive therapy follows the anabolic course.
PSI's reading: bisphosphonates and FDA-approved anabolic peptides hold complementary positioning per AACE/ACE 2020. Bisphosphonates are first-line for moderate fracture risk with substantial outcomes evidence. Anabolic peptides are appropriate for high fracture risk including severe osteoporosis with prior fragility fracture. Sequential therapy with antiresorptive following anabolic course is the validated framework. Specialty coordination ensures appropriate matching.
Romosozumab dual mechanism vs sequential anabolic-then-antiresorptive
Anti-sclerostin biologic vs Teriparatide-then-bisphosphonate sequence
Romosozumab (Evenity) provides dual anabolic and antiresorptive mechanism through sclerostin inhibition. The compound holds FDA approval for postmenopausal osteoporosis at high fracture risk approved 2019. FRAME Phase 3 demonstrated approximately 73 percent vertebral fracture reduction at 12 months. ARCH Phase 3 demonstrated superiority over alendronate. Treatment is 12 months with sequential antiresorptive therapy following. Cardiovascular boxed warning applies in patients with prior MI or stroke.
Sequential anabolic-then-antiresorptive with Teriparatide or Abaloparatide for 2 years followed by bisphosphonate or denosumab represents the traditional anabolic strategy per AACE/ACE 2020. Phase 3 evidence supports preserving anabolic gains with sequential antiresorptive therapy. Reverse sequence (antiresorptive then anabolic) blunts the anabolic response and is not recommended.
PSI's reading: Romosozumab and sequential anabolic-then-antiresorptive both represent FDA-approved validated strategies for high-risk postmenopausal osteoporosis per AACE/ACE 2020. Patient selection considers cardiovascular history (Romosozumab boxed warning), treatment duration preference (12 months vs 24 months anabolic), injection frequency (monthly vs daily), and prior fracture history. Specialty coordination ensures appropriate matching.
Postmenopausal vs male vs glucocorticoid-induced osteoporosis frameworks
Different guideline approaches
Postmenopausal osteoporosis follows AACE/ACE 2020 framework. Treatment thresholds include T-score below -2.5, FRAX 10-year fracture risk above 20 percent for major osteoporotic or 3 percent for hip, or prior fragility fracture. First-line includes bisphosphonates for moderate risk and anabolic peptides (Teriparatide, Abaloparatide, Romosozumab) for high risk per individualized assessment.
Male osteoporosis follows Endocrine Society 2019 framework. Treatment includes bisphosphonates as first-line, Teriparatide FDA-approved for men with primary or hypogonadal osteoporosis at high fracture risk, and Abaloparatide FDA-approved for male osteoporosis approved 2022. Romosozumab is NOT FDA-approved for men. Testosterone replacement is appropriate for hypogonadal men with osteoporosis.
Glucocorticoid-induced osteoporosis follows ACR 2017 framework. Treatment includes calcium and vitamin D supplementation as foundational, bisphosphonates as first-line for most patients, and Teriparatide as preferred anabolic option. The ACR 2017 framework provides specific treatment thresholds based on glucocorticoid dose, duration, and patient risk factors.
Comprehensive bone health management vs single-modality approach
Integrated multi-component therapy versus partial intervention
Bone health is multifactorial. Contributors include estrogen deficiency, age-related bone loss, secondary causes (hyperparathyroidism, hyperthyroidism, vitamin D deficiency, malabsorption, glucocorticoids), nutrition, physical activity, and fall risk. Comprehensive evaluation per AACE/ACE 2020 identifies all contributing factors. Validated comprehensive management addresses each factor with appropriate therapy under primary care, endocrinology, rheumatology, or geriatrics specialty guidance.
Comprehensive management addresses each component. Pharmacotherapy targets bone mineral density and fracture risk with bisphosphonates, denosumab, anabolic peptides, or Romosozumab per individualized assessment. Calcium 1200 mg daily and vitamin D 800-1000 IU daily are foundational supplementation. Weight-bearing exercise stimulates bone formation. Resistance training improves muscle mass and balance. Fall prevention reduces fracture risk in older adults. Smoking cessation supports bone health. Limited alcohol consumption supports bone density.
PSI's reading: comprehensive bone health management addresses multiple contributors with validated FDA-approved therapies under specialty coordination. Single-compound peptide approach addresses only one mechanism. Validated multi-component framework per AACE/ACE 2020 + Endocrine Society 2019 + ACR 2017 + Bone Health Osteoporosis Foundation provides foundation. Specialty coordination ensures appropriate matching.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 5 peptides discussed for bone health, three hold direct FDA-approved osteoporosis indications. Teriparatide (Forteo) is FDA-approved for postmenopausal osteoporosis, men with osteoporosis, and glucocorticoid-induced osteoporosis with PTH 1-34 anabolic mechanism. Phase 3 trials demonstrated approximately 65 percent reduction in vertebral fractures. Abaloparatide (Tymlos) is FDA-approved for postmenopausal and male osteoporosis at high fracture risk with PTHrP analog anabolic mechanism via ACTIVE Phase 3. Romosozumab (Evenity) is FDA-approved for postmenopausal osteoporosis at high fracture risk with anti-sclerostin dual anabolic and antiresorptive mechanism via ARCH and FRAME Phase 3 trials. Calcitonin (Miacalcin) is FDA-approved for postmenopausal osteoporosis with antiresorptive mechanism but use has declined due to malignancy concerns. BPC-157 is research-grade with limited clinical evidence. Validated standard-of-care including bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), denosumab (Prolia), SERMs (raloxifene Evista), calcium 1200 mg daily, vitamin D 800-1000 IU daily, weight-bearing exercise, and fall prevention under primary care, endocrinology, rheumatology, or geriatrics specialty guidance dominates evidence-graded bone health care per AACE/ACE 2020 + Endocrine Society 2019 + ACR 2017 frameworks.
Teriparatide
FDA-approved Forteo for postmenopausal + male + glucocorticoid osteoporosis. Phase 3 ~65% vertebral fracture reduction. Most established FDA-approved anabolic peptide.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Postmenopausal osteoporosis fracture reduction FDA-approved Forteo Phase 3 evidence | 8 PTH 1-34 anabolic effects in animal bone models. | 8 Phase 3 demonstrated 65 percent vertebral and 53 percent non-vertebral fracture reduction. Neer 2001 |
Glucocorticoid-induced osteoporosis FDA-approved Forteo + ACR 2017 preferred | 4 PTH effects in glucocorticoid-treated bone models. | 4 Phase 3 demonstrated superiority over alendronate in glucocorticoid osteoporosis. Saag 2007 |
Abaloparatide
FDA-approved Tymlos for postmenopausal (2017) + male (2022) osteoporosis at high fracture risk. ACTIVE Phase 3 ~86% vertebral fracture reduction.
| Context | Animal Studies | Human Trials |
|---|---|---|
Postmenopausal osteoporosis fracture reduction FDA-approved Tymlos ACTIVE Phase 3 | 6 PTHrP analog anabolic effects in animal bone models. | 6 ACTIVE Phase 3 demonstrated approximately 86 percent vertebral fracture reduction. Miller 2016 |
Romosozumab
FDA-approved Evenity for postmenopausal osteoporosis at high fracture risk (2019). Dual mechanism. FRAME ~73% reduction + ARCH superiority over alendronate. CV boxed warning.
| Context | Animal Studies | Human Trials |
|---|---|---|
Postmenopausal osteoporosis fracture reduction FDA-approved Evenity FRAME + ARCH Phase 3 | 6 Sclerostin inhibition increases bone formation in animal models. | 8 FRAME demonstrated 73 percent vertebral fracture reduction; ARCH superiority over alendronate. Cosman 2016, Saag 2017 |
Calcitonin
FDA-approved Miacalcin for postmenopausal osteoporosis. PROOF Phase 3 ~33% vertebral fracture reduction. Use declined per AACE/ACE 2020 due to malignancy concerns.
| Context | Animal Studies | Human Trials |
|---|---|---|
Postmenopausal osteoporosis fracture reduction FDA-approved Miacalcin PROOF Phase 3 | 4 Calcitonin antiresorptive effects in animal models. | 4 PROOF demonstrated 33 percent vertebral fracture reduction over 5 years. Chesnut 2000 |
BPC-157
Research-grade with animal model bone/tendon healing evidence. No human Phase 2/3 osteoporosis trials. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
Bone and tendon healing research Animal model evidence | 12 Animal model evidence for bone, tendon, ligament healing and angiogenic effects. | 0 No direct human bone or osteoporosis Phase 2/3 trials. Sikiric 2018 |
What's Marketed vs What's Studied
7 common claims, corrected.
“Anabolic peptides like Forteo can be used long-term.”
Anabolic peptides have time limits per FDA labeling. Teriparatide (Forteo) is limited to 2 years lifetime due to osteosarcoma concerns from preclinical rat studies. Abaloparatide (Tymlos) is limited to 2 years lifetime. Romosozumab (Evenity) treatment is 12 months due to plateau of effect. Sequential antiresorptive therapy with bisphosphonate or denosumab follows the anabolic course to preserve gains per AACE/ACE 2020.
“Compounded PTH peptides are equivalent to FDA-approved Forteo for osteoporosis.”
FDA-approved Forteo (teriparatide) has substantial Phase 3 evidence with quality control and regulatory oversight. Compounded peptides outside FDA-approved framework lack equivalent evidence and quality assurance. Osteoporosis management relies on FDA-approved products under primary care, endocrinology, rheumatology, or geriatrics specialty guidance per AACE/ACE 2020.
“All osteoporosis patients should start with anabolic peptide therapy.”
Bisphosphonates are first-line per AACE/ACE 2020 for moderate fracture risk with substantial outcomes evidence. Anabolic peptides (Teriparatide, Abaloparatide, Romosozumab) hold positioning for high fracture risk including severe osteoporosis with prior fragility fracture. Patient selection considers fracture risk classification, prior therapy, contraindications, and individualized assessment under specialty guidance.
“Calcium and vitamin D supplementation is unnecessary if I take medications.”
Calcium 1200 mg daily and vitamin D 800 to 1000 IU daily are foundational supplementation across all bone health care per AACE/ACE 2020. All anabolic and antiresorptive therapies require adequate calcium and vitamin D for optimal effect. Lifestyle is foundational and complementary to pharmacotherapy. Adequate intake supports bone formation, resorption regulation, and fracture prevention.
“Romosozumab is dangerous and rarely used due to cardiovascular concerns.”
Romosozumab (Evenity) is FDA-approved for postmenopausal osteoporosis at high fracture risk approved 2019 with substantial FRAME and ARCH Phase 3 evidence. The cardiovascular boxed warning applies in patients with prior MI or stroke and requires risk-benefit assessment. For appropriate patients without contraindications, the compound provides validated dual anabolic and antiresorptive therapy. Specialty guidance ensures appropriate selection.
“BPC-157 is FDA-approved for bone healing.”
BPC-157 is NOT FDA-approved for any indication including bone healing. The compound is research-only in the United States. Animal model evidence exists for bone, tendon, and ligament healing but no human Phase 2 or Phase 3 trials support clinical use. Validated bone health care relies on FDA-approved anabolic peptides (Teriparatide, Abaloparatide, Romosozumab), bisphosphonates, denosumab, calcium, vitamin D, and weight-bearing exercise per AACE/ACE 2020.
“I can self-treat osteoporosis with peptides without medical supervision.”
Comprehensive evaluation by primary care, endocrinology, rheumatology, or geriatrics identifies fracture risk, secondary causes, and matches treatment per AACE/ACE 2020. Workup includes DEXA T-score, FRAX 10-year fracture risk, calcium, vitamin D, and biochemical markers. Osteoporosis requires validated guideline-directed therapy with substantial outcomes evidence. Self-treatment bypasses essential clinical assessment and validated framework.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive osteoporosis evaluation.
DEXA T-score, FRAX 10-year fracture risk, calcium, vitamin D, and secondary cause assessment guide treatment per AACE/ACE 2020.
Establish primary care, endocrinology, rheumatology, or geriatrics.
Multi-specialty coordination is appropriate for complex osteoporosis. Endocrinology manages secondary causes. Rheumatology manages glucocorticoid-induced disease.
Optimize foundational calcium and vitamin D.
Calcium 1200 mg daily and vitamin D 800 to 1000 IU daily are required across all bone health care per AACE/ACE 2020.
Match therapy to fracture risk classification.
Bisphosphonates first-line for moderate risk. Anabolic peptides (Teriparatide, Abaloparatide, Romosozumab) for high risk per AACE/ACE 2020.
Plan sequential therapy from the start.
Anabolic-then-antiresorptive sequence preserves gains. Anabolic limited to 12-24 months. Bisphosphonate or denosumab follows.
Approach compounded peptides cautiously.
FDA-approved Forteo, Tymlos, and Evenity have substantial Phase 3 evidence. Compounded peptides outside FDA-approved framework are not validated practice.
The regulatory landscape for bone health peptides is evolving. Romosozumab (Evenity) received FDA approval for postmenopausal osteoporosis at high fracture risk in 2019. Abaloparatide (Tymlos) received FDA approval for male osteoporosis in 2022 expanding from initial 2017 postmenopausal approval. Teriparatide off-patent generics (e.g. Bonsity) became available expanding access. AACE/ACE 2020 + Endocrine Society 2019 + ACR 2017 frameworks provide guidance. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for osteoporosis?
Yes. Three peptide-class therapies hold direct FDA-approved osteoporosis indications. Teriparatide (Forteo) is FDA-approved for postmenopausal osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis. Abaloparatide (Tymlos) is FDA-approved for postmenopausal (2017) and male (2022) osteoporosis at high fracture risk. Romosozumab (Evenity) is FDA-approved for postmenopausal osteoporosis at high fracture risk approved 2019. Calcitonin (Miacalcin) is FDA-approved with declining use.
What is the AACE/ACE 2020 framework for osteoporosis?
AACE/ACE 2020 Postmenopausal Osteoporosis Clinical Practice Guideline establishes treatment thresholds based on T-scores and FRAX 10-year fracture risk. Treatment is indicated for T-score below -2.5, FRAX major osteoporotic fracture risk above 20 percent or hip fracture risk above 3 percent, or prior fragility fracture. First-line includes bisphosphonates for moderate risk and anabolic peptides (Teriparatide, Abaloparatide, Romosozumab) for high risk. Calcium 1200 mg and vitamin D 800-1000 IU daily are foundational. Specialty guidance ensures appropriate matching.
Should I see a primary care or specialty physician for osteoporosis?
Primary care typically manages routine osteoporosis evaluation and treatment for many patients. Endocrinology specialty manages complex osteoporosis, secondary causes, and treatment escalation. Rheumatology specialty manages osteoporosis with rheumatologic conditions or glucocorticoid-induced osteoporosis. Geriatrics specialty manages osteoporosis in older adults with fall risk. Multi-specialty coordination is common for complex patients. AACE/ACE 2020 framework provides guidance for specialty coordination.
What is the comprehensive evaluation for osteoporosis?
Comprehensive osteoporosis evaluation per AACE/ACE 2020 includes DEXA bone density T-score (lumbar spine, hip), FRAX 10-year fracture risk calculator, calcium, vitamin D 25-hydroxyvitamin D, complete blood count, basic metabolic panel, thyroid stimulating hormone, and 24-hour urine calcium when appropriate. Biochemical bone turnover markers (P1NP, CTX) apply for select cases. Secondary cause evaluation includes hyperparathyroidism, hyperthyroidism, hypogonadism, vitamin D deficiency, malabsorption, and glucocorticoid exposure assessment.
What is Teriparatide (Forteo)?
Teriparatide is recombinant human PTH 1-34 administered subcutaneously daily. The compound is FDA-approved as Forteo for postmenopausal osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and glucocorticoid-induced osteoporosis. Mechanism is intermittent PTH receptor activation stimulating osteoblast activity producing net anabolic bone effects. Phase 3 trials demonstrated approximately 65 percent reduction in vertebral fractures and 53 percent reduction in non-vertebral fractures. Treatment is limited to 2 years lifetime.
What is Abaloparatide (Tymlos)?
Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) administered subcutaneously daily. The compound is FDA-approved as Tymlos for postmenopausal osteoporosis at high fracture risk approved 2017 and male osteoporosis approved 2022. Mechanism is preferential PTH1 receptor RG conformation activation producing greater anabolic effects with less hypercalcemia than Teriparatide. ACTIVE Phase 3 demonstrated approximately 86 percent vertebral fracture reduction. Treatment is limited to 2 years lifetime.
What is Romosozumab (Evenity)?
Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein that suppresses Wnt signaling in osteoblasts. The compound is FDA-approved as Evenity for postmenopausal osteoporosis at high fracture risk approved 2019. Mechanism is sclerostin inhibition simultaneously increasing bone formation and decreasing bone resorption producing dual anabolic and antiresorptive effects. FRAME Phase 3 demonstrated 73 percent vertebral fracture reduction at 12 months. ARCH Phase 3 demonstrated superiority over alendronate. Treatment is 12 months. CV boxed warning applies.
What about bisphosphonates for osteoporosis?
Bisphosphonates are validated first-line antiresorptive therapy per AACE/ACE 2020 for moderate fracture risk. Alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast) are FDA-approved options. Mechanism is osteoclast inhibition through farnesyl pyrophosphate synthase blockade. Vertebral fracture reduction is approximately 40-70 percent. Treatment duration is typically 3-5 years with drug holiday consideration. Side effects include esophageal irritation (oral) and rare osteonecrosis of the jaw or atypical femoral fracture (long-term).
What about Denosumab (Prolia)?
Denosumab (Prolia) is FDA-approved RANKL inhibitor monoclonal antibody administered subcutaneously every 6 months. The compound provides validated antiresorptive therapy with FREEDOM Phase 3 fracture reduction evidence. Indication includes postmenopausal osteoporosis at high fracture risk, male osteoporosis, and glucocorticoid-induced osteoporosis. Discontinuation requires sequential bisphosphonate therapy due to rebound vertebral fracture risk. Specialty guidance ensures appropriate use.
What is sequential therapy for osteoporosis?
Sequential therapy involves anabolic peptide therapy (Teriparatide, Abaloparatide, or Romosozumab) followed by antiresorptive therapy (bisphosphonate or denosumab) to preserve anabolic gains per AACE/ACE 2020. Anabolic-then-antiresorptive sequence is the validated framework. Reverse sequence (antiresorptive then anabolic) blunts the anabolic response and is not recommended. Treatment durations are: Teriparatide and Abaloparatide 2 years lifetime, Romosozumab 12 months. Sequential antiresorptive therapy follows.
What about calcium and vitamin D for bone health?
Calcium 1200 mg daily and vitamin D 800 to 1000 IU daily are foundational supplementation across all bone health care per AACE/ACE 2020. Adequate intake supports bone formation, resorption regulation, and fracture prevention. All anabolic and antiresorptive therapies require adequate calcium and vitamin D for optimal effect. Dietary sources are preferred when possible. Vitamin D 25-hydroxyvitamin D measurement guides supplementation. Higher doses may be needed for deficiency.
What about exercise for bone health?
Weight-bearing exercise reduces fracture risk and supports bone health per AACE/ACE 2020. Recommended interventions include weight-bearing activities (walking, jogging, dancing) and resistance training (2-3 sessions weekly). Resistance training improves muscle mass and balance, reducing fall risk. Tai chi and balance training reduce falls in older adults. Comprehensive exercise programs combine weight-bearing, resistance, and balance components. Lifestyle is foundational and complementary to pharmacotherapy.
Are these peptides legal in the United States?
Teriparatide is FDA-approved as Forteo by Eli Lilly and now available as off-patent generics (Bonsity by Pfenex) by prescription. Abaloparatide is FDA-approved as Tymlos by prescription (originally Radius Health, now Paragon). Romosozumab is FDA-approved as Evenity by Amgen by prescription. Calcitonin is FDA-approved as Miacalcin and generics by prescription. BPC-157 is NOT FDA-approved and available only through research chemical suppliers and compounding pharmacies for off-label use.
What is glucocorticoid-induced osteoporosis?
Glucocorticoid-induced osteoporosis is bone loss caused by long-term glucocorticoid (corticosteroid) therapy. ACR 2017 framework provides specific treatment thresholds based on glucocorticoid dose, duration, and patient risk factors. Treatment includes calcium and vitamin D supplementation as foundational, bisphosphonates as first-line for most patients, and Teriparatide as preferred anabolic option. Patients on chronic glucocorticoids should be assessed for fracture risk at initiation and during therapy.
What about male osteoporosis?
Male osteoporosis follows Endocrine Society 2019 framework. Treatment includes bisphosphonates as first-line, Teriparatide FDA-approved for men with primary or hypogonadal osteoporosis at high fracture risk, and Abaloparatide FDA-approved for male osteoporosis approved 2022. Romosozumab is NOT FDA-approved for men in the US. Testosterone replacement is appropriate for hypogonadal men with osteoporosis. Comprehensive evaluation includes secondary cause assessment.
What questions should I ask my doctor about peptides for bone health?
Ask: (1) What is my comprehensive evaluation including DEXA T-score, FRAX 10-year fracture risk, calcium, vitamin D, and secondary cause assessment? (2) What is my fracture risk classification (moderate vs high)? (3) Am I a candidate for bisphosphonate first-line or anabolic peptide therapy? (4) Which anabolic peptide (Teriparatide, Abaloparatide, or Romosozumab) is appropriate? (5) What is my sequential therapy plan after the anabolic course? (6) Is calcium 1200 mg and vitamin D 800-1000 IU optimized? (7) Am I doing weight-bearing exercise and fall prevention?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.